3-(4,4-Difluoro-cyclohexyl)-acryloyl chloride | 1255710-98-5

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 英文名称: 3-(4,4-Difluoro-cyclohexyl)-acryloyl chloride
• 英文别名: 3-(4,4-difluorocyclohexyl)prop-2-enoyl chloride
• CAS: 1255710-98-5
• 化学式: C₉H₁₁ClF₂O
• 分子量: 208.636
• InChiKey: GBKPRELLFRAKGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4,4-Difluoro-cyclohexyl)-acryloyl chloride 在 对甲苯磺酸 、 三乙胺 作用下， 以 甲苯 为溶剂， 生成 5-bromo-2-[2-(4,4-difluorocyclohexyl)vinyl]-1H-benzimidazole
  参考文献：
  名称：

  Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia

  摘要：

  Thermosensitive transient receptor potential melastatin 8 (TRPM8) antagonists are considered to be potential therapeutic agents for the treatment of cold hypersensitivity. The discovery of a new class of TRPM8 antagonists that shows in vivo efficacy in the rat chronic constriction injury (CCI)-induced model of neuropathic pain is described. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.060

文献信息

• Benzimidazole derivatives useful as TRP M8 receptor modulators
  申请人：Janssen Pharmaceutica, NV

  公开号：US08217060B2

  公开（公告）日：2012-07-10

  The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8 (transient receptor potential M8 channel). More particularly, the compounds of the present invention are useful in the treatment of inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold, anxiety and depression.

  本发明涉及苯并咪唑衍生物、含有它们的制药组合物以及它们在治疗由TRP M8（瞬时受体电位M8通道）调节的疾病和症状中的应用。更具体地说，本发明的化合物在治疗炎症性疼痛、炎症性过敏症、炎症性过敏性症状、神经病理性疼痛、神经病理性冷痛觉、炎症性体感觉过敏症、炎症性内脏过敏症、寒冷加重的心血管疾病、焦虑和抑郁方面具有用处。
• BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS
  申请人：Calvo Raul R.

  公开号：US20100292276A1

  公开（公告）日：2010-11-18

  The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8 (transient receptor potential M8 channel). More particularly, the compounds of the present invention are useful in the treatment of inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold, anxiety and depression.

  本发明涉及苯并咪唑衍生物、含有它们的制药组合物以及它们在TRP M8（瞬时受体电位M8通道）调节的疾病和症状治疗中的应用。更具体地说，本发明的化合物在治疗炎性疼痛、炎性过敏症、炎性过敏性疾病、神经病理性疼痛、神经性冷痛觉过敏、炎性体表过敏症、炎性内脏过敏症、寒冷加重的心血管疾病、焦虑和抑郁方面具有用途。
• Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia
  作者：Raul R. Calvo、Sanath K. Meegalla、Daniel J. Parks、William H. Parsons、Shelley K. Ballentine、Mary Lou Lubin、Craig Schneider、Raymond W. Colburn、Christopher M. Flores、Mark R. Player

  DOI：10.1016/j.bmcl.2012.01.060

  日期：2012.3

  Thermosensitive transient receptor potential melastatin 8 (TRPM8) antagonists are considered to be potential therapeutic agents for the treatment of cold hypersensitivity. The discovery of a new class of TRPM8 antagonists that shows in vivo efficacy in the rat chronic constriction injury (CCI)-induced model of neuropathic pain is described. (c) 2012 Elsevier Ltd. All rights reserved.